Cite
MLA Citation
Patrice Chevallier et al.. “90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.” Lancet, vol. 2, no. 3, 2015, pp. e108–e117. http://access.bl.uk/ark:/81055/vdc_100066538459.0x000009